Physician profile
Sumit Som
NPI 1235559451
$700.91
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $30.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $194.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $144.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $104.98 | 2019 | |
| Pfizer INC. | $48.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.99 | 2019 | |
| Janssen Biotech, INC. | $36.57 | 2019 | |
| Novo Nordisk INC | $27.97 | 2019-2020 | |
| Genentech USA, INC. | $20.59 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $16.76 | 2019 | |
| Amarin Pharma, INC. | $16.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.17 | 2019 | |
| Philips North America LLC | $14.51 | 2020 | |
| Astellas Pharma US INC | $11.05 | 2019 | |
| Dynavax Technologies Corporation | $6.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Som listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.